Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.

Willits I, Price L, Parry A, Tilby MJ, Ford D, Cholerton S, Pearson AD, Boddy AV.

Br J Cancer. 2005 May 9;92(9):1626-35.

2.

Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.

Boddy AV, English M, Pearson AD, Idle JR, Skinner R.

Eur J Cancer. 1996 Jun;32A(7):1179-84.

PMID:
8758250
3.

Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients.

Johnstone EC, Lind MJ, Griffin MJ, Boddy AV.

Cancer Chemother Pharmacol. 2000;46(6):433-41.

PMID:
11138456
4.

Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration.

Boddy AV, Yule SM, Wyllie R, Price L, Pearson AD, Idle JR.

Cancer Chemother Pharmacol. 1996;38(2):147-54.

PMID:
8616905
5.

Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo.

Börner K, Kisro J, Brüggemann SK, Hagenah W, Peters SO, Wagner T.

Drug Metab Dispos. 2000 May;28(5):573-6.

6.

Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay.

Hartley JM, Spanswick VJ, Gander M, Giacomini G, Whelan J, Souhami RL, Hartley JA.

Clin Cancer Res. 1999 Mar;5(3):507-12.

7.

Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans.

Lokiec F, Santoni J, Weill S, Tubiana-Hulin M.

Anticancer Drugs. 1996 Nov;7(8):893-6.

PMID:
8991196
8.

[Ifosfamide and the metabolites of side chain oxidation--excretion in urine in various pediatric therapeutic protocols].

Boos J, Welslau U, Ritter J, Blaschke G, Schellong G.

Klin Padiatr. 1992 Jul-Aug;204(4):299-305. German.

PMID:
1518269
9.

Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.

Silies H, Blaschke G, Hohenlöchter B, Rossi R, Jürgens H, Boos J.

Int J Clin Pharmacol Ther. 1998 May;36(5):246-52.

PMID:
9629987
10.
11.
12.

New insights into the clinical pharmacokinetics of trofosfamide.

Brinker A, Kisro J, Letsch C, Brüggemann SK, Wagner T.

Int J Clin Pharmacol Ther. 2002 Aug;40(8):376-81.

PMID:
12467306
13.

Comparison of continuous infusion and bolus administration of ifosfamide in children.

Boddy AV, Yule SM, Wyllie R, Price L, Pearson AD, Idle JR.

Eur J Cancer. 1995;31A(5):785-90.

PMID:
7640054
14.
15.

Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma.

Jahnke K, Wagner T, Bechrakis NE, Willerding G, Coupland SE, Fischer L, Thiel E, Korfel A.

Ann Oncol. 2005 Dec;16(12):1974-8. Epub 2005 Oct 11.

PMID:
16219622
16.

Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients.

Boddy AV, Proctor M, Simmonds D, Lind MJ, Idle JR.

Eur J Cancer. 1995;31A(1):69-76.

PMID:
7695982
17.
18.

Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.

Chugh R, Wagner T, Griffith KA, Taylor JM, Thomas DG, Worden FP, Leu KM, Zalupski MM, Baker LH.

Cancer. 2007 Jun 1;109(11):2315-22.

19.

Ifosfamide nephrotoxicity in pediatric cancer patients.

Lee BS, Lee JH, Kang HG, Hahn H, Lee JH, Shin HY, Ha IS, Cheong HI, Ahn HS, Choi Y.

Pediatr Nephrol. 2001 Oct;16(10):796-9.

PMID:
11605785

Supplemental Content

Support Center